Congress Abstracts
- In adult patients with Type 1 diabetes, switching from real-time CGM (rtCGM) to intermittently-scanned CGM (isCGM) was associated with a signficant reduction in HbA1c that was sustained for up to 24 months.
- Among Medicaid beneficiaries with Type 2 diabetes treated with basal insulin in the USA, the acquisiton of continuous glucose monitoring (CGM) was associated with significant improvements in hospitlizations, emergency department visits, as well as outpatient visits when comparing pre- and post-CGM periods.
- Among Medicaid beneficiaries with Type 2 diabetes treated with multiple daily injections of insulin in the USA, the acquisiton of continuous glucose monitoring (CGM) was associated with significant improvements in hospitalizations, emergency department visits, as well as outpatient visits when comparing pre- and post-CGM periods.
- In people with Type 2 diabetes with elevated HbA1c on prior GLP-1 RA therapy, the acquisition of FreeStyle Libre was associated with a significant reduction in HbA1c, irrespective of GLP-1 RA duration, GLP-1 RA type, or insulin therapy type.
- In people with Type 2 diabetes with elevated HbA1c, the initiation of GLP-1 RA therapy and FreeStyle Libre was associated with a significant reduction in HbA1c compared to those initiating GLP-1 RA therapy alone.
- At a willingness-to-pay threshold of $100,000 (USD) per quality adjusted life years (QALY) gained, the addition of FreeStyle Libre in people with Type 2 diabetes on GLP-1 RA therapy led to higher costs but more QALY gained compared to initiating GLP-1 RA therapy alone.
- In both non-hispanic white and black children and adults with Type 1 diabetes, the personalized estimated average glucose (peAG) using each individual's personal glycation ratio (PGR) demonstrated a more accurate estimate of average glycemia dervied from HbA1c compared to the estimated average glucose (eAG).
- A novel approach for evaluating red blood cell (RBC) glucose uptake demonstrated a large variation in glucose uptake across donor samples, with samples from donors of black ancestry demonstrating higher mean uptake than those with white ancestry.
- Among 4,082 people with Type 1 or Type 2 diabetes using rapid-acting insulin, data from CGM and connected insulin pens suggests that glucose monitoring behavior is more predictive of overall glucose control than dosing behavior.
- In a retrospective analysis of data from Bigfoot Unity Management System from users with Type 1 and 2 diabetes, CGM data availabilty of less than 70% did not show substantiatlly higher average HbA1c estimation errors when compared with GMI.
- Retrospective data obtained from users with Type 1 and 2 diabetes using the Bigfoot Unity Management System for MDI demonstrated an association between changes to insulin therapy settings and improved CGM-derived outcomes.
- Minimum Morning Glucose (MMG), a novel CGM-derived metric for estimating fasting blood glucose, may serve as a useful tool for guiding long-acting insulin dose titation in individuals with Type 1 and 2 diabetes.
- Clinically significant A1C and AG-derived A1C discordance is common, particularly in Black individuals. Personalized A1C addresses this discrepancy potentially improving clinical management in diabetes and reducing health disparities.
- People with T2DM not using insulin showed large, clinically significant improvements in CGM metrics and HbA1c when using either FSL CGM alone or FSL CGM plus a food logging application.
- A subgroup analysis of the RELIEF study suggests that use of the FSL is associated with reduced hospital admissions for ADEs in people with T2DM treated with oral insulin-secretagogue drugs without insulin. Results suggest FSL may help support treatment optimization and reduce treatment inertia.
- Compared to pre-FSL use, patients using FSL with type 2 diabetes treated with SU/meglitinides had lower healthcare utilization. Further research should assess the financial and patient impact of these event reductions.
- A retrospective cohort study shows that frequent use of FSL plays a pivotal role in glucose management among people with T2D treated with basal insulin and GLP-1 RAs, where consistent FSL use is associated with sustained glycemic control, and inconsistent FSL use is associated with worsened glycemic outcomes.
- After FreeStyle Libre adoption, HbA1c was statistically significantly improved across age groups, and there was a reduced total healthcare burden related to ED visits and hospitalization rates (overall, for DKA, and for hypoglycemia).
- From a Canadian private payer perspective, FreeStyle systems are cost effective compared with SMBG for all peopleliving with diabetes.
- In people with insulin-treated T2DM, initiation of is CGM is associated with reduced HbA1c and reduced relative risk for hospitalization compared with BGM controls
- In adults with T1DM, initiating is CGM is associated with reduced HbA1c and reduced rates of hospitalization compared with BGM controls
- There is high similarity between HbA1c and GMI-BG in the DCCT for indication of sustained progression of retinopathy, despite the intermittent but structured 7-point BG measurement
CE/CME Programs
- Supporting Healthy Eating Habits through Continuous Glucose Monitors (CGMs)
- Taking a Personalized Approach to Diabetes Management With iCGM: A Look at Advancing Technology, Data Comprehension, and the Pharmacist's Role
- 2024 PTCE Diabetes Day of Education: Best Practices for Optimizing Integrated Continuous Glucose Monitoring
- Integrating and applying CGM technology for improved primary care management of type 2 diabetes
- Integrated Continuous Glucose Monitoring Implementation and Connectivity: Best Practices, Featuring a Powered by Patients™ Interview
stay connected